Can Fite Biofarma (Can Fite Biofarma) Total Assets

: $9.99 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

Can Fite Biofarma's Total Assets for the quarter that ended in Dec. 2023 was $9.99 Mil.

During the past 12 months, Can Fite Biofarma's average Total Assets Growth Rate was -17.70% per year. During the past 3 years, the average Total Assets Growth Rate was -3.30% per year. During the past 5 years, the average Total Assets Growth Rate was -27.00% per year. During the past 10 years, the average Total Assets Growth Rate was 4.00% per year.

During the past 13 years, Can Fite Biofarma's highest 3-Year average Total Assets Growth Rate was 80.90%. The lowest was -37.90%. And the median was 4.30%.

Total Assets is connected with ROA %. Can Fite Biofarma's annualized ROA % for the quarter that ended in Dec. 2023 was -68.98%. Total Assets is also linked to Revenue through Asset Turnover. Can Fite Biofarma's Asset Turnover for the quarter that ended in Dec. 2023 was 0.02.

Can Fite Biofarma Total Assets Historical Data

The historical data trend for Can Fite Biofarma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

8.17

9.52

20.25

9.28

9.99

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets																9.28	13.49	11.03	9.17	9.99

Can Fite Biofarma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Can Fite Biofarma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	6.243	+	3.746
	=	9.99

Can Fite Biofarma's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	6.243	+	3.746
	=	9.99

Can Fite Biofarma (AMEX:CANF) Total Assets Explanation

Total Assets is connected with ROA %.

Can Fite Biofarma's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-6.608	/	( (9.169	+	9.989)	/ 2 )
	=	-6.608	/	9.579
	=	-68.98 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Can Fite Biofarma's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0.155	/	( (9.169	+	9.989)	/ 2 )
=	0.155	/	9.579
=	0.02

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Can Fite Biofarma Total Assets Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).